Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 23 October 2025 - 14 December 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 15, 2025 US market open with a familiar “big pharma” setup—steady cash returns, blockbuster execution, and a pipeline that’s increasingly being treated as a source of upside rather than a safety net. Shares last traded around $223.32, slipping modestly at Friday’s close as broader markets softened, but ABBV remains one of the stronger large-cap pharma performers in 2025. MarketWatch ABBV before the bell: the quick read What’s driving the narrative into December 15 1) Analysts are turning more constructive—and targets moved up fast Two notable Wall Street signals landed just ahead
14 December 2025
·····
AbbVie Stock Outlook (ABBV): Weekly Recap, Fresh Analyst Upgrades, and the Week-Ahead Setup (Updated Dec. 12, 2025)

AbbVie Stock Outlook (ABBV): Weekly Recap, Fresh Analyst Upgrades, and the Week-Ahead Setup (Updated Dec. 12, 2025)

AbbVie Inc. (NYSE: ABBV) ended the week of Dec. 8–12, 2025 near $223, after a choppy stretch that featured two notable Wall Street moves—an HSBC upgrade and a Morgan Stanley price-target hike—alongside ongoing headlines tied to AbbVie’s oncology and neuroscience pipeline. Yahoo Finance+2MarketBeat+2 For investors, the near-term story remains a familiar one: ABBV’s share price is being pulled between defensive-dividend appeal (especially in an uncertain macro backdrop) and the market’s ongoing debate over how durable AbbVie’s post-Humira growth engine will be—driven mainly by Skyrizi and Rinvoq, plus a deepening pipeline. AbbVie News Center+1 ABBV stock this week: Where AbbVie shares
14 December 2025
····
AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

(SEO): AbbVie (NYSE: ABBV) ended the week at $223.32. Here’s what moved ABBV stock this week, the latest news, analyst forecasts and price targets, and what to watch in the week ahead. StockAnalysis Updated:Friday, December 12, 2025 (U.S. market close) MarketWatch ABBV stock today: Where AbbVie shares finished, and how the week played out AbbVie shares closed Friday at $223.32, down 0.29% on the day, in a broader risk-off session where the S&P 500 fell 1.07%. MarketWatch+1 This week’s trading snapshot (Dec. 8–12): Daily closes (for quick context): The latest AbbVie news driving the stock in the last few days
13 December 2025
·····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2 At the same time, the stock is still trading below its early‑October high, and investors are weighing Humira’s ongoing decline, softness in aesthetics, and regulatory risk against that growth story. Here’s a detailed look
11 December 2025
·····
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 as one of the most closely watched large‑cap healthcare stocks, with fresh dividend news, new oncology and migraine data, and an upbeat earnings outlook all hitting the tape just as investors look toward 2026. As of December 2, 2025, AbbVie shares trade around $224–$225 per share, giving the company a market capitalization in the high‑$300 to roughly $400 billion range.TS2 Tech The stock is up roughly 20–30% in 2025, depending on the exact start date used, handily outpacing much of the broader healthcare sector.Barchart.com+2Benzinga+2 Below is a deep dive
2 December 2025
·····
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock.The Motley Fool+1 Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and how Wall Street now frames the 2026 outlook. AbbVie stock today: price, performance and valuation As of the December 1, 2025 close, AbbVie shares trade at around $225 per share, giving the company a market capitalization near $400 billion.StockAnalysis+1 Key snapshot
1 December 2025
·····
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. (NYSE: ABBV) heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30. As of the latest close on November 30, AbbVie shares are trading in the mid‑$220s — around $227 per share — after a strong year (roughly 30%+ total return over the past 12 months) but a softer week in which the stock slipped about 3% as traders reacted to Medicare pricing headlines and year‑end profit‑taking. TS2 Tech+1 At this level the stock offers a dividend yield a
30 November 2025
·····
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 with a mixed but generally constructive backdrop for shareholders. The stock is trading in the mid‑$220s per share — around $227 — implying a market capitalization of roughly $400 billion and a dividend yield in the low‑3% range. StockAnalysis+1 Year to date, AbbVie stock is up more than 30%, comfortably ahead of the broader market, even after a modest pullback in recent sessions. Tokenist+1 At the same time, fresh Medicare pricing pressure, a high headline price-to-earnings ratio and the latest analyst rating change on November 30 are giving investors
30 November 2025
·····
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1 Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. Simply Wall St+1 Today’s news flow (November 29, 2025) gives investors plenty to chew on: Below is a
29 November 2025
·····
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie Inc. (NYSE: ABBV) is trading lower today, but the big pharma giant remains near multi-year highs as investors digest a powerful mix of good news (a major FDA approval, strong Q3 numbers) and growing policy headwinds from U.S. Medicare drug price cuts. Below is a full wrap-up of what’s happening with AbbVie stock today, November 26, 2025, and the key headlines driving sentiment. AbbVie (ABBV) stock price today: mild pullback after strong run As of early afternoon U.S. trading on Wednesday, AbbVie stock is changing hands around $227.41, down about 1.9% on the day. The shares opened at $232.04,
26 November 2025
····
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on recordts2.techreportify.cn. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits)timesunion.comreportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1stts2.tech. Several catalysts have fueled this rally. In mid-September, AbbVie announced a patent settlement securing no U.S. generics for Rinvoq until 2037, effectively
31 October 2025
·····
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on recorddirectorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8 (reached on Oct. 1)ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its key drug
23 October 2025
·····
1 … 4 5 6 7

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop